The Bethesda System For Reporting Thyroid Cytop... Now

The sample did not have enough cells to make a diagnosis. II: Benign: High probability of being non-cancerous.

It categorizes thyroid nodules into six distinct groups based on the fine needle aspiration cytology (FNAC) results, each associated with a specific risk of malignancy (RoM) and recommended management: The Bethesda System for Reporting Thyroid Cytop...

It ensures that a "suspicious" result means the same thing, regardless of which lab processed it. The sample did not have enough cells to make a diagnosis

The (ROM) for each Bethesda category The 2023 updates to the system How it compares to the TIRADS system for imaging Let me know which area you'd like to explore further. The (ROM) for each Bethesda category The 2023

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Bethesda System for Reporting Thyroid Cytopathology Defin

Before this system was finalized (originally around 2010 and updated in 2023), different laboratories used different terms to describe thyroid fine-needle aspiration (FNA) samples, causing confusion for clinicians. The Bethesda System was developed through an NIH-sponsored conference to create a common language.

Each category helps clinicians understand the likelihood of malignancy to guide treatment (e.g., surveillance vs. surgery).